Literature DB >> 8796377

The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats.

A Zarif1, D Eiznhamer, C Callaghan, M I Doria, L Broutman, A Keshavarzian.   

Abstract

Though the mechanism of tissue damage induced by colonic inflammation in ulcerative colitis is unknown, it has been established that the inflammatory mediator and potent neutrophil (PMN) chemotaxin, leukotriene B4(LTB4), is present in elevated amounts in the inflamed mucosa. The unique role of 5-lipoxygenase in the production of leukotrienes has made it a target for inhibition. This study used a rat model of acute colonic inflammation induced by a single IP injection of Mitomycin-C to test the efficacy of a specific and potent 5-lipoxygenase inhibitor zileuton in the treatment of colonic inflammation. We hypothesized that after inducing colitis in rats with mitomycin-C, the administration of oral zileuton would inhibit leukotriene production, thus preventing PMN infiltration and subsequent tissue damage. Zileuton decreased colonic tissue damage as measured by Histological score. However, zileuton did not significantly decrease neutrophil infiltration measured by mucosal PMN or myeloperoxidase (MPO) levels. Although zileuton was successful in significantly decreasing the frequency of severe colitis in our model, the fact that the decrease in PMN count and MPO level was not statistically significant suggests that another mechanism may be involved in its anti-inflammatory effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8796377     DOI: 10.1007/bf01488200

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  20 in total

Review 1.  Recent developments in nonspecific inflammatory bowel disease (second of two parts).

Authors:  J B Kirsner; R G Shorter
Journal:  N Engl J Med       Date:  1982-04-08       Impact factor: 91.245

2.  Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis.

Authors:  T Nishida; H Miwa; A Shigematsu; M Yamamoto; M Iida; M Fujishima
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

3.  Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe.

Authors:  A Keshavarzian; S Sedghi; J Kanofsky; T List; C Robinson; C Ibrahim; D Winship
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

4.  Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis.

Authors:  C Collawn; P Rubin; N Perez; J Bobadilla; G Cabrera; E Reyes; J Borovoy; D Kershenobich
Journal:  Am J Gastroenterol       Date:  1992-03       Impact factor: 10.864

5.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

6.  The effect of methotrexate on lipoxygenase metabolism in neutrophils from rats: in vitro and ex vivo studies.

Authors:  J S Hawkes; L G Cleland; M J James
Journal:  Agents Actions       Date:  1993-11

7.  Mitomycin C-induced colitis in rats: a new animal model of acute colonic inflammation implicating reactive oxygen species.

Authors:  A Keshavarzian; M I Doria; S Sedghi; J R Kanofsky; D Hecht; E W Holmes; C Ibrahim; T List; G Urban; T Gaginella
Journal:  J Lab Clin Med       Date:  1992-11

Review 8.  Neuropeptides and gastrointestinal immunity.

Authors:  M S O'Dorisio
Journal:  Am J Med       Date:  1986-12-22       Impact factor: 4.965

Review 9.  Review: lipoxygenase inhibitors and the gut.

Authors:  N P Kennedy; P W Keeling
Journal:  Aliment Pharmacol Ther       Date:  1987-08       Impact factor: 8.171

10.  Selective 5-lipoxygenase inhibition in ulcerative colitis.

Authors:  L S Laursen; J Naesdal; K Bukhave; K Lauritsen; J Rask-Madsen
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  2 in total

Review 1.  The enzymology and pharmacology of 5-lipoxygenase and 5-lipoxygenase activating protein.

Authors:  R L Bell; R R Harris
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase.

Authors:  B J R Whittle; C Varga; A Berko; K Horvath; A Posa; J P Riley; K A Lundeen; A M Fourie; P J Dunford
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.